These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 15006984)

  • 1. Identical twins with primary pulmonary hypertension: beraprost vs epoprostenol.
    Berman Rosenzweig E; Schmitt KA; Garofano R; Barst RJ
    Chest; 2004 Mar; 125(3):1157-60. PubMed ID: 15006984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beraprost therapy for pulmonary arterial hypertension.
    Barst RJ; McGoon M; McLaughlin V; Tapson V; Rich S; Rubin L; Wasserman K; Oudiz R; Shapiro S; Robbins IM; Channick R; Badesch D; Rayburn BK; Flinchbaugh R; Sigman J; Arneson C; Jeffs R;
    J Am Coll Cardiol; 2003 Jun; 41(12):2119-25. PubMed ID: 12821234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostanoid therapy for pulmonary arterial hypertension.
    Badesch DB; McLaughlin VV; Delcroix M; Vizza CD; Olschewski H; Sitbon O; Barst RJ
    J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):56S-61S. PubMed ID: 15194179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disproportionate pulmonary hypertension in a patient with early-onset pulmonary emphysema treated with specific drugs for pulmonary arterial hypertension.
    Shimizu M; Imanishi J; Takano T; Miwa Y
    Intern Med; 2011; 50(20):2341-6. PubMed ID: 22001462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful management of portopulmonary hypertension with beraprost.
    Kim EJ; Shin MS; Oh KY; Kim MG; Shin KC; Park YM; Kim BR; Chung WJ; Ahn TH; Choi IS; Shin EK
    Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1503-5. PubMed ID: 21389799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy.
    Seyfarth HJ; Pankau H; Hammerschmidt S; Schauer J; Wirtz H; Winkler J
    Chest; 2005 Aug; 128(2):709-13. PubMed ID: 16100158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension.
    Saji T; Ozawa Y; Ishikita T; Matsuura H; Matsuo N
    Am J Cardiol; 1996 Jul; 78(2):244-7. PubMed ID: 8712155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beraprost sodium for pulmonary hypertension with congenital heart disease.
    Suzuki H; Sato S; Tanabe S; Hayasaka K
    Pediatr Int; 2002 Oct; 44(5):528-9. PubMed ID: 12225555
    [No Abstract]   [Full Text] [Related]  

  • 9. New and experimental therapies for pulmonary hypertension.
    Channick RN; Rubin LJ
    Clin Chest Med; 2001 Sep; 22(3):539-45. PubMed ID: 11590847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostacyclin therapy for pulmonary arterial hypertension: new directions.
    Gomberg-Maitland M; Preston IR
    Semin Respir Crit Care Med; 2005 Aug; 26(4):394-401. PubMed ID: 16121316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High levels of nitric oxide in individuals with pulmonary hypertension receiving epoprostenol therapy.
    Ozkan M; Dweik RA; Laskowski D; Arroliga AC; Erzurum SC
    Lung; 2001; 179(4):233-43. PubMed ID: 11891614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beraprost therapy in children with pulmonary hypertension secondary to congenital heart disease.
    Limsuwan A; Pienvichit P; Khowsathit P
    Pediatr Cardiol; 2005; 26(6):787-91. PubMed ID: 16132278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary arterial hypertension in a Kartagener syndrome patient: treatment with beraprost sodium.
    Shen YC; Wen FQ; Yi Q
    Int J Cardiol; 2012 Aug; 159(1):e9-10. PubMed ID: 22104985
    [No Abstract]   [Full Text] [Related]  

  • 14. Beneficial hemodynamic effects of oral prostacyclin (PGI2) analogue, beraprost sodium, on a patient with primary pulmonary hypertension--a case report.
    Hashida H; Hamada M; Shigematsu Y; Ikeda S; Kuwahara T; Kawakami H; Hara Y; Kodama K; Kohara K; Hiwada K
    Angiology; 1998 Feb; 49(2):161-4. PubMed ID: 9482517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A survey of diagnostic practices and the use of epoprostenol in patients with primary pulmonary hypertension.
    Robbins IM; Christman BW; Newman JH; Matlock R; Loyd JE
    Chest; 1998 Nov; 114(5):1269-75. PubMed ID: 9824000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Oral administration of beraprost sodium did not exacerbate pulmonary hypertension with CREST syndrome].
    Furukawa K; Ikeda S; Obase K; Muroya T; Oka H; Kojima M; Miyahara Y; Kohno S
    Nihon Naika Gakkai Zasshi; 2001 May; 90(5):881-3. PubMed ID: 11460359
    [No Abstract]   [Full Text] [Related]  

  • 17. Perfusion lung scan as a prognostic indicator of response to beraprost sodium in idiopathic pulmonary arterial hypertension.
    Park SY; Moon DH; Park YB; Na JO; Whang HK; Lim BS; Lee SD
    Pulm Pharmacol Ther; 2006; 19(4):264-71. PubMed ID: 16139536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.
    McLaughlin VV; Shillington A; Rich S
    Circulation; 2002 Sep; 106(12):1477-82. PubMed ID: 12234951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pulmonary hypertension].
    Olschewski H; Ghofrani A; Wiedemann R; Rose F; Enke B; Gessler T; Voswinckel R; Kohstall M; Grimminger F; Seeger W
    Internist (Berl); 2002 Dec; 43(12):1498, 1501-9. PubMed ID: 12607389
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of pulmonary arterial hypertension.
    Humbert M; Sitbon O; Simonneau G
    N Engl J Med; 2004 Sep; 351(14):1425-36. PubMed ID: 15459304
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.